Michal Laniado Schwartzman, M.Sc., Ph.D., began her tenure in the Department of Pharmacology in 1981 as a postdoctoral fellow supported by an NIH Fogarty Fellowship. She rose through the academic ranks and was promoted to full professor in 1993. Since 2010, Dr. Schwartzman has led the department—initially as acting chair and officially appointed chair the following year. A recipient of numerous honors, including the Dean's Distinguished Research Award, she has maintained uninterrupted NIH funding since 1981. In 2025, she was appointed the Alumni Endowed Chair in Biomedical Sciences. Dr. Schwartzman has contributed extensively to the scientific community through her service on NIH study sections, review panels, and editorial boards. She currently serves as editor of the Journal Prostaglandins and Other Lipid Mediators.

Education

• B.Sc., Biology, Tel-Aviv University
• M.Sc., Biochemistry, Tel-Aviv University
• Ph.D., Biochemistry, Tel-Aviv University

Areas of Expertise

• Cardiovascular Pharmacology
• Hypertension

Honors and Awards

• Fogarty International Fellowship
• Irma T. Hirschl Career Scientist Award
• Mathers Foundation Scientist Award
• The Tinsley Harrison Award for Cardiovascular Research
• The Dean's Distinguished Research Award

Research

Dr. Schwartzman is nationally and internationally recognized for her research which focuses on the role of eicosanoids of the cytochrome P450 pathway, primarily 20-HETE, in the regulation of vascular function, inflammation and metabolism in the areas of cardiovascular and metabolic diseases. The chemical structure, biological function and mechanism of action of some of these lipids have been identified in Dr. Schwartzman’s laboratory.

Currently, she is utilizing gene targeting, transgenic animals and human material to 1) elucidate the pathophysiological significance of 20-HETE in promoting disease; 2) identify the mechanisms underlying the bioaction of this vasoactive proinflammatory lipid; and 3) develop small molecules to block its action. Dr. Schwartzman has published more than 245 manuscripts in peer-reviewed journals, including Nature, Science, PNAS, JCI and Circulation Research.

Publications

• Schwartzman ML. "An editorial farewell." Prostaglandins & other lipid mediators, 177(), (2025) 106950. doi: 10.1016/j.prostaglandins.2025.106950
• Fragner ML, Parikh MA, Jackson KA, et. al. "GPR75: A Newly Identified Receptor for Targeted Intervention in the Treatment of Obesity and Metabolic Syndrome." Cardiology in review, (), (2024) . doi: 10.1097/CRD.0000000000000711
• D'Addario CA, Matsumura S, Kitagawa A, et. al. "Global and endothelial G-protein coupled receptor 75 (GPR75) knockout relaxes pulmonary artery and mitigates hypoxia-induced pulmonary hypertension." Vascular pharmacology, 153(), (2023) 107235. doi: 10.1016/j.vph.2023.107235
• Pascale JV, Wolf A, Kadish Y, et. al. "20-Hydroxyeicosatetraenoic acid (20-HETE): Bioactions, receptors, vascular function, cardiometabolic disease and beyond." Advances in pharmacology (San Diego, Calif.), 97(), (2023) 229-255. doi: 10.1016/bs.apha.2023.01.002
• Hossain S, Gilani A, Pascale J, et. al. "Gpr75-deficient mice are protected from high-fat diet-induced obesity." Obesity (Silver Spring, Md.), 31(4), (2023) 1024-1037. doi: 10.1002/oby.23692
• Azcona JA, Tang S, Berry E, et. al. "Neutrophil-Derived Myeloperoxidase and Hypochlorous Acid Critically Contribute to 20-Hydroxyeicosatetraenoic Acid Increases that Drive Postischemic Angiogenesis." The Journal of pharmacology and experimental therapeutics, 381(3), (2022) 204-216. doi: 10.1124/jpet.121.001036
• Agostinucci K, Hutcheson R, Hossain S, et. al. "Blockade of 20-hydroxyeicosatetraenoic acid receptor lowers blood pressure and alters vascular function in mice with smooth muscle-specific overexpression of CYP4A12-20-HETE synthase." Journal of hypertension, 40(3), (2022) 498-511. doi: 10.1097/HJH.0000000000003038

View All Publications

Professional Service

• Chair, Appointment, Promotion and Tenure Committee
• Editor, Prostaglandins and Other Lipid Mediators (Elsevier)